Drugs / AZD7687
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01217905 | Nov 2010 → Jul 2011 | obesity disorder, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01119352 | Apr 2010 → Mar 2011 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01046357 | Nov 2009 → Jun 2010 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7687 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119352 ↗ |
| Action | Inhibit | “Diacylglycerol O-acyltransferase 1 inhibitor” CHEMBL4297354 ↗ |
| Modality | Small molecule | — CHEMBL4297354 ↗ |
| Route | Oral | “Single oral dose” NCT01046357 ↗ |
| Target | DGAT1 | “Diacylglycerol O-acyltransferase 1 inhibitor” CHEMBL4297354 ↗ |